ArticleInternational journal of nanomedicine2025
Self-Assembled Nanoplatform with pH/NIR Light-Responsive Drug Delivery for Combined Therapy of Glioma in vitro.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Global research trends and emerging frontiers of nanozymes in cancer therapy based on bibliometric and knowledge mapping analysis from 2001 to 2025.Discover nano · 2026Review
- Overcoming barriers: mechanisms and strategies of nanoparticles in overcoming the blood-brain barrier and drug resistance in glioblastomas.Journal of the Egyptian National Cancer Institute · 2026Review
- Electrochemical Sensing of Doxorubicin in Breast Cancer Cells Based on Membrane-Permeation Strategy.Molecules (Basel, Switzerland) · 2026Article
- Mapping two decades of nanomaterials research in glioblastoma: trends, networks, and translational insights.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Research progress on glioma drug resistance: mechanism analysis and therapeutic strategies.Frontiers in pharmacology · 2026Review
- Next-Generation Anticancer Peptides: Engineering, Nanotheranostics and Clinical Translation.Nanotheranostics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The integration of multifunctional components into a single nanoplatform offers significant potential for personalized and minimally invasive therapeutic applications. Herein, we present a facile yet versatile strategy to engineer a near-infrared (NIR) pH- and light-responsive nanomaterial, demonstrating promising efficacy in glioblastoma combination therapy through multimodal synergistic mechanisms. Methods: The FEID nanoplatform was engineered by co-assembling ICG, DOX, and Fe³⁺. Systematic characterization included physicochemical properties (TEM, DLS, UV-vis-NIR spectroscopy, zeta potential measurements, and XPS), photothermal conversion efficiency, Fenton reaction kinetics, PTT-enhanced CDT performance, laser-triggered drug release patterns, and NIR-responsive drug release and dual-modal imaging (fluorescence/MRI) capabilities. Intracellular DOX accumulation and ROS generation were confirmed by confocal laser scanning microscopy and flow cytometry in U87 glioma cells. Hemolysis assay, cytotoxicity profiling against normal 293T and RAW264.7 cells, and H&E staining were applied for biosafety assessment. The synergistic anti-glioblastoma efficacy was systematically evaluated through MTT assays, live/dead cell staining, and apoptosis detection via Annexin V/PI staining. The pharmacokinetic profiles and blood-brain barrier (BBB) permeability of the FEID were analyzed in vivo. Results: The FEID nanoplatform displayed uniform spherical morphology (78.2 nm average diameter). pH/NIR-triggered release of DOX (chemotherapy) and ICG (PTT), combined with GSH depletion and NIR irradiation, synergistically enhanced Fe²⁺-mediated CDT. This multimodal therapy demonstrated potent cytotoxicity against U87 glioblastoma cells (14.8% cell viability). Furthermore, ICG fluorescence recovery and MRI contrast enabled tumor imaging, while enhanced BBB permeability ensured effective drug delivery for in situ glioma treatment. Conclusion: In summary, we developed a safe FEID anti-tumor nanoplatform through a simple self-assembly process. This platform demonstrates the potential for controlled drug release and efficient combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.